Introduction

Details

• Alternative Title:
  J Low Genit Tract Dis
• Personal Author:
  Gargano, Julia W. ; Wilkinson, Edward J. ; Unger, Elizabeth R. ; Steinau, Martin ; Watson, Meg ; Huang, Youjie ; Copeland, Glenn ; Cozen, Wendy ; Goodman, Marc T. ; Hopenhayn, Claudia ; Lynch, Charles F. ; Hernandez, Brenda Y. ; Peters, Edward S. ; Saber, Maria Sibug ; Lyu, Christopher W. ; Sands, Lauren A. ; Saraiya, Mona
• Description:
  Objective
  
  To determine the baseline prevalence of human papillomavirus (HPV) types in invasive vulvar cancers (IVC) and vulvar intraepithelial neoplasia 3 (VIN3) using data from 7 United States cancer registries.
  
  Materials and Methods
  
  Registries identified eligible cases diagnosed in 1994–2005 and requested pathology laboratories to prepare one representative block for HPV testing on those selected. Hematoxylin and eosin stained (H&E) sections preceding and following those used for extraction were reviewed to confirm representation. HPV was detected using L1 consensus PCR with PGMY9/11 primers and type specific hybridization, with retesting of negative and inadequate samples with SPF10 primers. For IVC, the confirmatory H&E slides were re-evaluated to determine histologic type. Descriptive analyses were performed to examine distributions of HPV by histology and other factors.
  
  Results
  
  HPV was detected in 121/176 (68.8%) IVC and 66/68 (97.1%) VIN3 (p<.0001). IVC and VIN3 differed by median age (70 years vs. 55 years, p=.003). HPV16 was present in 48.6% of IVC and 80.9% of VIN3; other high-risk (HR) HPV was present in 19.2% of IVC and 13.2% of VIN3. HPV prevalence differed by squamous cell carcinoma (SCC) histologic subtype (p<.0001): keratinizing, 49.1% (n=55); non-keratinizing, 85.7% (n=14), basaloid, 92.3% (n=14), warty 78.2% (n=55), and mixed warty/basaloid, 100% (n=7).
  
  Conclusions
  
  Nearly all VIN3 and two-thirds of IVC were HR-HPV positive. HPV prevalence ranged from 49.1–100% across SCC histologic subtypes. Given the high prevalence of HPV in IVC and VIN3, prophylactic vaccines have the potential to decrease the incidence of vulvar neoplasia.
  
  
• Subjects:
  Adult Aged Aged, 80 And Over Carcinoma In Situ DNA, Viral Female Genotype Histocytochemistry Humans Microscopy Middle Aged Papillomaviridae Papillomavirus Infections Polymerase Chain Reaction Prevalence Viral Structural Proteins Vulvar Neoplasms

  More +
• Source:
  J Low Genit Tract Dis. 16(4):471-479.
• Pubmed ID:
  22652576
• Pubmed Central ID:
  PMC5553114
• Document Type:
  Journal Article
• Funding:
  N01-PC-35137/PC/NCI NIH HHS/United States ; N01-PC-35139/PC/NCI NIH HHS/United States ; 1U58DP000807-3/DP/NCCDPHP CDC HHS/United States ; 5U58DP000769-5/DP/NCCDPHP CDC HHS/United States ; 5U58DP000810-5/DP/NCCDPHP CDC HHS/United States ; Intramural NIH HHS/United States ; N01-PC-2010-00035/PC/NCI NIH HHS/United States ; CC999999/Intramural CDC HHS/United States ; 5U58DP000812-5/DP/NCCDPHP CDC HHS/United States ; N01-PC-35143/PC/NCI NIH HHS/United States ; 5U58DP000844-5/DP/NCCDPHP CDC HHS/United States
• Place as Subject:
  United States
• Volume:
  16
• Issue:
  4
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:7b530e8451787fad05c2c1be1f090c5b68c734a109620d6fd58f8cdd37410286
• Download URL:
  https://stacks.cdc.gov/view/cdc/47484/cdc_47484_DS1.pdf
• File Type:
  [PDF - 108.06 KB ]